Quick Answer
Silence Therapeutics plc reported Net Income Loss of -$88.61 million for the year ending 2025.
- Silence Therapeutics plc showed a decrease of -95.6% in Net Income Loss from 2024 to 2025.
- This data is from Silence Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$2.31 million | Q2 2024: -$19.76 million | Q3 2024: -$35.54 million | Q1 2025: -$28.53 million | Q2 2025: -$27.35 million | Q3 2025: -$20.96 million.
- Over the full 4 years of available data (2022 to 2025), Silence Therapeutics plc's Net Income Loss has declined by 76.0%.
- Historical annual values: Fiscal year 2025: -$88.61 million | Fiscal year 2024: -$45.31 million | Fiscal year 2023: -$54.23 million | Fiscal year 2022: -$50.33 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: